Ligand-targeted therapeutics in anticancer therapy

Nature Reviews Cancer

Volumn 2, Issue 10, 2002, Pages 750-763

  Allen, Theresa M ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CARCINOEMBRYONIC ANTIBODY; CD19 ANTIBODY; CYCLOPHOSPHAMIDE; DACLIZUMAB; DENILEUKIN DIFTITOX; DOXORUBICIN; EPRATUZUMAB; FOLIC ACID; GALACTOSAMINE; GEMTUZUMAB OZOGAMICIN; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IBRITUMOMAB TIUXETAN; IMATINIB; INTERLEUKIN 2 RECEPTOR ANTIBODY; LIGAND; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY LYM 1; PACLITAXEL; RADIOPHARMACEUTICAL AGENT; RITUXIMAB; TENASCIN ANTIBODY; TOPOTECAN; TOSITUMOMAB I 131; TRANSFERRIN; TRASTUZUMAB; TUMOR ANTIGEN; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASCULOTROPIN ANTIBODY; VINCRISTINE; YTTRIUM 90; ANTINEOPLASTIC AGENT; IMMUNOGLOBULIN G; IMMUNOTOXIN; POLYMER;

CANCER CELL; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER RADIOTHERAPY; CARDIOTOXICITY; CLINICAL TRIAL; CYTOTOXICITY; DRUG TARGETING; HUMAN; PRIORITY JOURNAL; REVIEW; SUSTAINED RELEASE PREPARATION; BIOLOGICAL MODEL; CHEMISTRY; METABOLISM; NEOPLASM; PROTEIN BINDING; RADIOIMMUNOTHERAPY;

ANTINEOPLASTIC AGENTS; HUMANS; IMMUNOGLOBULIN G; IMMUNOTOXINS; LIGANDS; MODELS, BIOLOGICAL; NEOPLASMS; POLYMERS; PROTEIN BINDING; RADIOIMMUNOTHERAPY;

EID: 0036781811     PISSN: 1474175X     EISSN: None     Source Type: Journal    
DOI: 10.1038/nrc903     Document Type: Review

References (121)

1. Carter, P. Improving the efficacy of antibody-based cancer therapies. Nature Rev. Cancer 1, 118-129 (2001).
2. Huston, J. S. & George, A. J. Engineered antibodies take center stage. Hum. Antibodies 10, 127-142 (2001).
3. Park, J. W. et al. Anti-HER2 immunoliposomes: enhanced efficacy attributable to targeted delivery. Clin. Cancer Res. 8, 1172-1181 (2002). Carefully controlled research study that describes the therapeutic effects in xenograft breast cancer models of anti-ERBB2-targeted immunoliposomes. This might be the first immunoliposome to enter clinical trials.
4. Drummond, D. C., Hong, K., Park, J. W., Benz, C. C. & Kirpotin, D. B. Liposome targeting to tumors using vitamin and growth factor receptors. Vitam. Horm. 60, 285-332 (2001).
5. Senter, P. D. & Springer, C. J. Selective activation of anticancer produugs by monoclonal antibody-enzyme conjugates. Adv. Drug Del. Rev. 53, 247-264 (2001).
6. Maynard, J. & Georgiou, G. Antibody engineering. Annu. Rev. Biomed. Eng. 2, 339-376 (2000).
7. Noonberg, S. B. & Benz, C. C. Tyrosine kinase inhibitors targeted to the epidermal growth factor receptor subfamily: role as anticancer agents. Drugs 59, 753-767 (2000)
8. Borisch, B., Semac, I., Soltermann, A., Palomba, C. & Hoessli, D. C. Anti-CD20 treatments and the lymphocyte membrane: pathology for therapy. Verh. Dtsch. Ges. Pathol. 85, 161-166 (2001).
9. Baselga, J. Herceptin alone or in combination with chemotherapy in the treatment of HER2-positive metastatic breast cancer: pivotal trials. Oncology 61 (Suppl. 2), 14-21 (2001).
10. Vose, J. M. et al. Phase II study of rituximab in combination with CHOP chemotherapy in patients with previously untreated, aggressive non-Hodgkin's lymphoma. J. Clin. Oncol. 19, 389-397 (2001).
11. Kohler, G. & Milstein, C. Continuous cultures of fused cells secreting antibody of predetermined specificity. Nature 256, 495-497 (1975).
12. Dillman, R. O. Human antimouse and antiglobulin responses to monoclonal antibodies. Antidody Immunoconjugates Radiopharm. 3, 1 (1990).
13. Dillman, R. O. Monoclonal antibodies in the treatment of malignancy: basic concepts and recent developments. Cancer Invest. 19, 833-841 (2001).
14. vs. Int. J. Cancer 94, 717-726 (2001).
15. Juweid, M. et al. Micropharmacology of monoclonal antibodies in solid tumors: direct experimental evidence for a binding site barrier. Cancer Res. 52, 5144-5153 (1992).
16. Banerjee, R. K., van Osdol, W. W., Bungay, P. M., Sung, C. & Dedrick, R. L. Finite element model of antibody penetration in a prevascular tumor nodule embedded in normal tissue. J. Control Release 74, 193-202 (2001).
17. v antibody molecules. Cancer Res. 61, 4750-4755 (2001).
18. Lopes de Menezes, D. E., Pilarski, L. M. & Allen, T. M. In vitro and in vivo targeting of immunoliposomal doxorubicin to human B-cell lymphoma. Cancer Res. 58, 3320-3330 (1998).
19. Ruoslahti, E. & Rajotte, D. An address system in the vasculature of normal tissues and tumors. Annu. Rev. Immunol. 18, 813-827 (2000).
20. Brekken, R. A. & Thorpe, P. E. Vascular endothelial growth factor and vascular targeting of solid tumors. Anticancer Res. 21, 4221-4229 (2001).
21. Hashizume, H. et al. Openings between defective endothelial cells explain tumor vessel leakiness. Am. J. Pathol. 156, 1363-1380 (2000).
22. Ruoslahti, E. Specialization of tumor vasculature. Nature Rev. Cancer 2, 83-90 (2002).
23. Yuan, F. et al. Vascular permeability in a human tumor xenograft: molecular size dependence and cutoff size. Cancer Res. 55, 3752-3756 (1995).
24. Stohrerm, M., Boucher, Y., Stangassinger, M. & Jain, R. K. Oncotic pressure in solid tumors is elevated. Cancer Res. 60, 4251-4255 (2000).
25. Yuan, F. et al. Microvascular permeability and interstitial penetration of sterically stabilized (Stealth) liposomes in a human tumor xenograft. Cancer Res. 54, 3352-3356 (1994).
26. Allen, T. M., Hansen, C. B. & Stuart, D. D. in Medical Applications of Liposomes (eds Lasic, D. D. & Papahadjopoulos, D.) 297-323 (Elsevier Science, Amsterdam, 1998).
27. Ercan, M. T. & Caglar, M. Therapeutic radiopharmaceuticals. Curr. Pharm. Des. 6, 1085-1121 (2000).
28. Goldenberg, D. M. Targeted therapy of cancer with radiolabeled antibodies. J. Nucl. Med. 43, 693-713 (2002).
29. Wagner, H. N. J. et al. Administration guidelines for radioimmunotherapy of non-Hodgkin's lymphoma with (90)Y-labeled anti-CD20 monoclonal antibody. J. Nucl. Med. 43, 267-272 (2002).
30. Kaminski, M. S. et al. Pivotal study of iodine I131 tositumomab for chemotherapy-refractory low-grade or transformed low-grade B-cell non-Hodgkin's lymphomas. J. Clin. Oncol. 19, 3908-3911 (2001). An important clinical study showing that patients who had failed several chemotherapy regimens had significantly increased responses to RAIT compared with their last qualifying chemotherapy.
31. Kaminski, M. S. et al. Iodine I131 tositumomab therapy for previously untreated follicular lymphoma. Proc. Am. Soc. Clin. Oncol. Ann. Meet. 19, Abstract 11 (2000).
32. DeNardo, G. L. et al. Are radiometal-labeled antibodies better than iodine-131-labeled antibodies: comparative pharmacokinetics and dosimetry of copper-67-, iodine-131-, and yttrium-90-labeled Lym-1 antibody in patients with non-Hodgkin's lymphoma. Clin. Lymphoma 1, 118-126 (2000).
33. Leonard, J. P. & Link, B. K. Immunotherapy of non-Hodgkin's lymphoma with hLL2 (epratuzumab, an anti-CD22 monoclonal antibody) and Hu1D10 (apolizumab). Semin. Oncol. 29 (Suppl. 2), 81-86 (2002).
34. Linden, O. et al. Radioimmunotherapy using 131I-labeled anti-CD22 monoclonal antibody (LL2) in patients with previously treated B-cell lymphomas. Clin. Cancer Res. 5, 3287s-3291s (1999).
35. Juweid, M. E. et al. Pharmacokinetics, dosimetry, and initial therapeutic results with 131I- and (111)In-/90Y-labeled humanized LL2 anti-CD22 monoclonal antibody in patients with relapsed, refractory non-Hodgkin's lymphoma. Clin. Cancer Res. 5, 3292s-3303s (1999).
36. Postema, E. J., Boerman, O. C., Oyen, W. J., Raemaekers, J. M. & Corstens, F. H. Radioimmunotherapy of B-cell non-Hodgkin's lymphoma. Eur. J. Nucl. Med. 28, 1725-1735 (2001).
37. Jurcic, J. G. Antibody therapy for residual disease in acute myelogenous leukemia. Crit. Rev. Oncol. Hematol. 38, 37-45 (2001).
38. Burke, J. M., Jurcic, J. G. & Scheinberg, D. A. Radioimmunotherapy for acute leukemia. Cancer Control 9, 106-113 (2002).
39. Dillman, R. O. Monoclonal antibody therapy for lymphoma: an update. Cancer Pract. 9, 71-80 (2001).
40. Goldenberg, D. M. The role of radiolabeled antibodies in the treatment of non-Hodgkin's lymphoma: the coming of age of radioimmunotherapy. Crit. Rev. Oncol. Hematol. 39, 195-201 (2001).
41. Casey, J. L. et al. Tumour targeting of humanised cross-linked divalent-Fab′ antibody fragments: a clinical phase I/II study. Br. J. Cancer 86, 1401-1410 (2002).
42. Barbet, J. et al. Pretargeting with the affinity enhancement system for radioimmunotherapy. Cancer Biother. Radiopharm. 14, 153-166 (1999).
43. Gestin, J. F. et al. Two-step targeting of xenografted colon carcinoma using a bispecific antibody and 188Re-labeled bivalent hapten: biodistribution and dosimetry studies. J. Nucl. Med. 42, 146-153 (2001).
44. Gautherot, E. et al. Pretargeted radioimmunotherapy of human colorectal xenografts with bispecific antibody and 131I-labeled bivalent hapten. J. Nucl. Med. 41, 480-487 (2000).
45. Kennel, S. J. et al. Vascular-targeted radioimmunotherapy with the alpha-particle emitter (211)at. Radiat. Res. 157, 633-641 (2002).
46. Duvic, M. et al. Quality-of-life improvements in cutaneous T-Cell lymphoma patients treated with denileukin diftitox (ONTAK(R)). Clin. Lymphoma 2, 222-228 (2002).
47. Olsen, E. et al. Pivotal phase III trial of two dose levels of denileukin diftitox for the treatment of cutaneous T-cell lymphoma. J. Clin. Oncol. 19, 376-388 (2001). Clinical trial that describes the results and side effects of the only immunotoxin that has been approved so far, showing that patients with persistent or recurrent cutaneous T-cell lymphoma have a 30% response rate, but experienced a 25% rate of vascular leak syndrome.
48. Schindler, J., Sausville, E. A., Messmann, R., Uhr, J. W. & Vitetta, E. S. The toxicity of deglycosylated ricin A chain-containing immunotoxins in patients with non-Hodgkin's lymphoma is exacerbated by prior radiotherapy: a retrospective analysis of patients in five clinical trials. Clin. Cancer Res. 7, 255-258 (2001).
49. Multani, P. S., O'Day, S., Nadler, L. M. & Grossbard, M. L. Phase II clinical trial of bolus infusion anti-B4 blocked ricin immunoconjugate in patients with relapsed B-cell non-Hodgkin's lymphoma. Clin. Cancer Res. 4, 2599-2604 (1998).
50. Dinndorf, P. et al. Phase I trial of anti-B4-blocked ricin in pediatric patients with leukemia and lymphoma. J. Immunother. 24, 511-516 (2001).
51. Grossbard, M. L. et al. A Phase II study of adjuvant therapy with anti-B4-blocked ricin after autologous bone marrow transplantation for patients with relapsed B-cell non-Hodgkin's lymphoma. Clin. Cancer Res. 5, 2392-2398 (1999).
52. Messmann, R. A. et al. A phase I study of combination therapy with immunotoxins IgG-HD37-deglycosylated ricin A chain (dgA) and IgG-RFB4-dgA (Combotox) in patients with refractory CD19(+), CD22(+) B cell lymphoma. Clin. Cancer Res. 6, 1302-1313 (2000).
53. Baluna, R., Rizo, J., Gordon, B. E., Ghetie, V. & Vitetta, E. S. Evidence for a structural motif in toxins and interleukin-2 that may be responsible for binding to endothelial cells and initiating vascular leak syndrome. Proc. Natl Acad. Sci. USA 96, 3957-3962 (1999). An important research study showing that a three-amino-acid sequence motif in toxins is responsible for binding to and damaging endothelial cells, causing vascular leak syndrome.
54. Baluna, R., Coleman, E., Jones, C., Ghetie, V. & Vitetta, E. S. The effect of a monoclonal antibody coupled to ricin A chain-derived peptides on endothelial cells in vitro: insights into toxin-mediated vascular damage. Exp. Cell Res. 258, 417-424 (2000).
55. Vitetta, E. S. Immunotoxins and vascular leak syndrome. Cancer J. 6, S218-S224 (2000).
56. Hu, R.-G., Zhai, Q.-W., He, W.-J., Mei, L. & Liu, W.-Y. Bioactivities of ricin retained and its immunoreactivity to anti-ricin polyclonal antibodies alleviated through pegylation. Int. J. Biochem. Cell Biol. 34, 396-402 (2002).
57. Wei, B. R., Ghetie, M. A. & Vitetta, E. S. The combined use of an immunotoxin and a radioimmunoconjugate to treat disseminated human B-cell lymphoma in immunodeficient mice. Clin. Cancer Res. 6, 631-642 (2000).
58. Kreitman, R. J. Toxin-labeled monoclonal antibodies. Curr. Pharm. Biotechnol. 2, 313-325 (2001).
59. Frankel, A. E. Increased sophistication of immunotoxins. Clin. Cancer Res. 8, 942-944 (2002).
60. Pennell, C. A. & Erickson, H. A. Designing immunotoxins for cancer therapy. Immunol. Res. 25, 177-191 (2002).
61. v fragments that had increased cytotoxicity against anti-CD22-expressing malignant cells.
62. Frankel, A. E., Powell, B. L., Hall, P. D., Case, L. D. & Kreitman, R. J. Phase I trial of a novel diphtheria toxin/granulocyte macrophage colony-stimulating factor fusion protein (DT388GMCSF) for refractory or relapsed acute myeloid leukemia. Clin. Cancer Res. 8, 1004-1013 (2002).
63. Garnett, M. C. Targeted drug conjugates: principles and progress. Adv. Drug Del. Rev. 53, 171-216 (2001).
64. Tolcher, A. W. et al. Randomized phase II study of BR96-doxorubicin conjugate in patients with metastatic breast cancer. J. Clin. Oncol. 17, 478-484 (1999).
65. Newton, D. L., Hansen, H. J., Mikulski, S. M., Goldenberg, D. M. & Rybak, S. M. Potent and specific antitumor effects of an anti-CD22-targeted cytotoxic ribonuclease: potential for the treatment of non-Hodgkin lymphoma. Blood 97, 528-535 (2001).
66. Sievers, E. L. et al. Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse. J. Clin. Oncol. 19, 3244-3254 (2001). Clincial trial of the first approved immunoconjugate, showing that 30% of patients achieved remission, but a high incidence of myelosuppression and hyperbilirubinaemia was observed.
67. Stadtmauer, E. A. Trials with gemtuzumab ozogamicin (Mylotarg) combined with chemotherapy regimens in acute myeloid leukemia. Clin. Lymphoma 2 (Suppl. 1), S24-S28 (2002).
68. Dubowchik, G. M. & Walker, M. A. Receptor-mediated and enzyme-dependent targeting of cytotoxic anticancer drugs. Pharm. Therap. 83, 67-123 (1999).
69. Napier M. P. et al. Antibody-directed enzyme prodrug therapy: efficacy and mechanism of action in colorectal carcinoma. Clin. Cancer Res. 6, 765-772 (2000).
70. Xu, G. & McLeod, H. L. Strategies for enzyme/prodrug cancer therapy. Clin. Cancer Res. 7, 3314-3324 (2001).
71. v::carboxypeptidase G2 fusion protein. Int. J. Cancer 85, 571-577 (2000). Description of a new approach to ADEPT, in which both the targeting agent and the prodrug-converting enzyme are included together in a recombinant fusion protein.
72. Hansen, C. B., Kao, G. Y., Moase, E. H., Zalipsky, S. & Allen, T. M. Attachment of antibodies to sterically stabilized liposomes: evaluation, comparison and optimization of coupling procedures. Biochim. Biophys. Acta 1239, 133-144 (1995).
73. Torchilin, V. P. et al. p-Nitrophenylcarbonyl-PEG-PE-liposomes: fast and simple attachment of specific ligands, including monoclonal antibodies, to distal ends of PEG chains via p-nitrophenylcarbonyl groups. Biochim. Biophys. Acta 1511, 397-411 (2001).
74. Ishida, T., Iden, D. L. & Allen, T. M. A combinatorial approach to producing sterically stabilized (Stealth) immunoliposomal drugs. FEBS Lett. 460, 129-133 (1999). Description of a simple new technique for converting non-targeted liposomal drugs into targeted immunoliposomes that can be tailored to individual patient disease profiles, thereby overcoming one of the manufacturing barriers to clinical trials of immunoliposomes.
75. Iden, D. L. & Allen, T. M. In vitro and in vivo comparison of immunoliposomes made by conventional coupling techniques with those made by a new post-insertion technique. Biochim. Biophys. Acta 1513, 207-216 (2001).
76. Moreira, J. N., Ishida, T., Gaspar, R. & Allen, T. M. Use of the post-insertion technique to insert peptide ligands into pre-formed Stealth liposomes with retention of binding activity and cytotoxicity. Pharm. Res. 19, 265-269 (2002).
77. Rosenecker, J. et al. Increased liposome extravasation in selected tissues: effect of substance P. Proc. Natl Acad. Sci. USA 93, 7236-7241 (1996).
78. Kong, G. et al. Efficacy of liposomes and hyperthermia in a human tumor xenograft model: importance of triggered drug release. Cancer Res. 60, 6950-6957 (2000).
79. Allen, T. M. & Moase, E. H. Therapeutic opportunities for targeted liposomal drug delivery. Adv. Drug Del. Rev. 21, 117-133 (1996).
80. Drummond, D. C., Meyer, O., Hong, K. L., Kirpotin, D. B. & Papahadjopoulos, D. Optimizing liposomes for delivery of chemotherapeutic agents to solid tumors. Pharmacol. Rev. 51, 691-743 (1999).
81. Li, W. M., Mayer, L. D. & Bally, M. B. Prevention of antibody-mediated elimination of ligand-targeted liposomes by using poly(ethylene glycol)-modified lipids. J. Pharmacol. Exp. Therapeut. 300, 976-983 (2002).
82. Allen, T. M., Sapra, P., Moase, E., Moreira, J. N. & Iden, D. L. Adventures in targeting. J. Liposome Res. 121, 5-12 (2002).
83. Nielsen, U. et al. Therapeutic efficacy of anti-ErbB2 immunoliposomes targeted by a phage antibody selected for cellular endocytosis. Biochem. Biophys. Acta 1591, 109-118 (2002).
84. Park, J. W. et al. Tumor targeting using anti-Her2 immunoliposomes. J. Control. Release 74, 95-113 (2001).
85. Lopes de Menezes, D. E., Pilarski, L. M., Belch, A. R. & Allen, T. M. Selective targeting of immunoliposomal doxorubicin against human multiple myeloma in vitro and ex vivo. Biochim. Biophys. Acta 1466, 205-220 (2000).
86. Boman, N. L., Masin, D., Mayer, L. D., Cullis, P. R. & Bally, M. B. Liposomal vincristine which exhibits increased drug retention and increased circulation longevity cures mice bearing P388 tumors. Cancer Res. 54, 2830-2833 (1994).
87. Ishida, T., Kirchmeier, M. J., Moase, E. H., Zalipsky, S. & Allen, T. M. Targeted delivery and triggered release of liposomal doxorubicin enhances cytotoxicity against human B lymphoma cells. Biochim. Biophys. Acta 1515, 144-158 (2001).
88. Needham, D. & Dewhirst, M. W. The development and testing of a new temperature-sensitive drug delivery system for the treatment of solid tumors. Adv. Drug Deliv. Rev. 53, 285-305 (2001).
89. Sharma, A., Straubinger, R. M., Ojima, I. & Bernacki, R. J. Antitumor efficacy of taxane liposomes on a human ovarian tumor xenograft in nude athymic mice. J. Pharm. Sci. 84, 1400-1404 (1995).
90. Lu, Z.-R., Shiah, J.-G., Sakuma, S., Kopeckova, P. & Kopecek, J. Design of novel bioconjugates for targeted drug delivery. J. Control. Rel. 78, 165-173 (2002).
91. David, A., Kopeckova, P., Rubinstein, A. & Kopecek, J. Enhanced bioorecognition and internalization of HMPA copolymers containing multiple or multivalent carbohydrate side-chains by human hepatocarcinoma cells. Bioconjugate Chem. 12, 890-899 (2001).
92. Seymour, L. W. et al. Hepatic drug targeting: Phase I evaluation of polymer-bound doxorubion. J. Clin. Oncol. 20, 1668-1676 (2002). Results of the only clinical trial so far that uses immunopolymers, demonstrating that the targeted therapy increased delivery of immunopolymers to tumours in patients with metastatic liver cancer.
93. Hovorka, O. et al. Differences in the intrcellular fate of free and polymer-bound doxorubicin. J. Control Release 80, 101-117 (2002).
94. Lopes de Menezes, D. E., Kirchmeier, M. J., Gagne, J.-F., Pilarski, L. M. & Allen, T. M. Cellular trafficking and cytotoxicity of anti-CD19-targeted liposomal doxorubicin in B lymphoma cells. J. Liposome Res. 9, 199-228 (1999).
95. Kirchmeier, M. J., Ishida, T., Chevrette, J. & Allen, T. M. Correlations between the rate of intracellular release of endocytosed liposomal doxorubicin and cytotoxicity as determined by a new assay. J. Liposome Res. 11, 15-29 (2001).
96. Satchi, R., Connors, T. A. & Duncan, R. PDEPT: polymer-directed enzyme prodrug therapy. I. HPMA copolymer-cathepsin B and PK1 as a model combination. Br. J. Cancer 85, 1070-1076 (2001).
97. Simoes, S., Slepushkin, V., Duzgunes, N. & Pedroso de Lima, M. C. On the mechanisms of internatilzation and intracellular delivery mediated by pH-sensitive liposomes. Biochim. Biophys. Acta 1515, 23-37 (2001).
98. Turk, M. J., Reddy, J. A., Chmielewski, J. A. & Low, P. S. Characterization of a novel pH-sensitive peptide that enhances drug release from folate-targeted liposomes at endosomal pHs. Biochim. Biophys. Acta 1559, 56-68 (2002).
99. Hong, M.-S., Lim, S.-J., Oh, Y.-K. & Kim, C.-K. pH-sensitive, serum-stable and long-circulating liposomes as a new drug delivery system. J. Pharm. Pharmacol. 54, 51-58 (2002).
100. Pasqualini, R. et al. Aminopeptidase N is a receptor for tumor-homing peptides and a target for inhibiting angiogenesis. Cancer Res. 60, 722-727 (2000).
101. Lee, R. J. & Low, P. S. Folate-targeted liposomes for drug delivery. J. Liposome Res. 7, 455-466 (1997).
102. Gabizon, A. et al. Targeting folate receptor with folate linked to extremities of poly(ethylene glycol)-grafted liposomes: in vitro studies. Bioconjugate Chem. 10, 289-298 (1999).
103. Ishida, O. et al. Liposomes bearing polyethyleneglycol-coupled transferrin with intracellular targeting property to the solid tumors in vivo. Pharm. Res. 18, 1042-1048 (2001).
104. Derycke, A. S. L. & De Witte, P. A. M. Transferrin-mediated targeting of hypericin embedded in sterically stabilized PEG-liposomes. Int. J. Oncol. 20, 181-187 (2002).
105. Brekken, R. A. et al. Selective inhibition of vascular endothelial growth factor (VEGF) receptor 2 (KDR/Flk-1) activity by a monoclonal anti-VEGF antibody blocks tumor growth in mice. Cancer Res. 60, 5117-5124 (2000).
106. v)-PE38 (LMB-2) in patients with hematologic malignancies. J. Clin. Oncol. 18, 1622-1636 (2000).
107. Reardon, D. A. et al. Phase II trial of murine (131)I-labeled antitenascin monoclonal antibody 81C6 administered into surgically created resection cavities of patients with newly diagnosed malignant gliomas. J. Clin. Oncol. 20, 1389-1397 (2002).
108. Behr, T. M. et al. Radioimmunotherapy of small-volume disease of metastatic colorectal cancer. Cancer 94 (Suppl. 4), 1373-1381 (2002).
109. Epenetos, A. A., Hird, V., Lambert, H., Mason, P. & Coulter, C. Long term survival of patients with advanced ovarian cancer treated with intraperitoneal radioimmunotherapy. Int. J. Gynecol. Cancer 10 (S1), 44-46 (2000).
110. Meredith, R. F. et al. Phase II study of interferon-enhanced 131I-labeled high affinity CC49 monoclonal antibody therapy in patients with metastatic prostate cancer. Clin. Cancer Res. 5 (Suppl. 10), 3254s-3258s (1999).
111. 90yttrium Zevalin (anti-CD20) gave superior clinical outcome compared with immunotherapy with the non-radiolabelled correlate rituximab (Rituxan).
112. Witzig, T. E. et al. Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma. J. Clin. Oncol. 20, 2453-2463 (2002).
113. Schnell, R. et al. Treatment of refractory Hodgkin's lymphoma patients with an anti-CD25 ricin A-cahin immunotoxin. Leukemia 14, 129-135 (2000).
114. Kreitman, R. J. et al. Efficacy of the anti-CD22 recombinant immunotoxin BL22 in chemotherapy-resistant hairy-cell leukemia. N. Engl. J. Med. 345, 241-247 (2001).
115. Thompson, J. et al. Improved binding of a bivalent single-chain immunotoxin results in increased efficacy for in vivo T-cell depletion. Protein Eng. 14, 1035-1041 (2001).
116. Engebraaten, O., Hjortland, G. O., Juell, S., Hirschberg, H. & Fodstad, O. Intratumoral immunotoxin treatment of human malignant brain tumors in immunodefficient animals. Int. J. Cancer 97, 846-852 (2002).
117. Strome, S. E. et al. Interleukin 4 receptor-directed cytotoxin therapy for human head and neck squamous cell carcinoma in animal models. Clin. Cancer Res. 8, 281-286 (2002).
118. Thomas, P. B., Delatte, S. J., Sutphin, A., Frankel, A. E. & Tagge, E. P. Effective targeted cytotoxicity of neuroblastoma cells. J. Pediatr. Surg. 37, 539-544 (2002).
119. Peipp, M. et al. A recombinant CD7-specific single-chain immunotoxin is a potent inducer of apoptosis in acute leukemic T cells. Cancer Res. 62, 2848-2855 (2002).
120. Shinohara, H. et al. Expression of HER2 in human gastric cancer cells directly correlates with antitumor activity of a recombinant disulfide-stabilized anti-HER2 immunotoxin. J. Surg. Res. 102, 169-177 (2002).
121. Veenendaal, L. M. et al. In vitro and in vivo studies of a VEGF121/rGelonin chimeric fusion toxin targeting the neovasculature of solid tumors. Proc. Natl Acad. Sci. USA 99, 7866-7871 (2002).